Xeljanz (tofacitinib)

pCPA File Number: 20877

Negotiation Status:

Concluded with an LOI

Indication(s):

Rheumatoid Arthritis

Sponsor/Manufacturer:

Pfizer Canada ULC

CDA-AMC Project Number:

SR0380-000

pCPA Engagement Letter Issued:

2015-07-21

Negotiation Process Concluded:

2016-04-26